Sentences with phrase «efficacy of drug treatments»

The long - term efficacy of drug treatments is unknown in terms of the accumulation of disability and the prognosis of relapsing - remitting MS.. A better understanding of the neuroprotective effects of available drugs and newer compounds is needed,» the authors conclude.

The organs - on - chips can then be used to test the efficacy of drug treatments on a particular organ.

Not exact matches

Rather, it's the no - holds - barred sales practices that Alexion allegedly engaged in — which, in some cases, reportedly led to salespeople bullying doctors into prescribing the drug for patients even when the efficacy of the treatment was unclear.

Insurers like Anthem have refused to cover the exorbitantly pricey treatment (around $ 300,000) since the drug's label admits that Exondys hasn't proved its efficacy, making the therapy a roll of the dice for payers and patients alike.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The three - armed trial evaluated the efficacy of chiropractic spinal manipulative therapy (CSMT) in the treatment of migraine versus placebo (sham chiropractic) and control (usual drug treatment).

The researchers hope that ultimately human trials will prove the efficacy of the OH14 compound in sensitising tumour cells and cancer stem cells to existing drug - based therapies thus disabling tumours from seeding new growth after treatment.

Schlom, of the National Cancer Institute, says the next challenge for researchers is to find ways to combine different immunotherapy drugs into single treatments and measure their efficacy in clinical trials.

Exploiting the same pre-clinical model used for their studies, the researchers are testing the efficacy of this kind of drug candidates against cancer stem cells, and the possibility of identifying combination regimens with standard chemotherapies with minimized toxic effects, with the perspective of their possible application for the treatment of human breast cancer.

A new study led by University of Kentucky researchers suggests a new approach to develop highly - potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.

«We can also use these models to test the efficacy and safety of new cancer treatment therapies and cancer drugs.»

Results from recent clinical trials and studies in animals suggest that a class of anti-cancer drugs called angiogenesis inhibitors may be able to temporarily reduce interstitial pressure and improve the efficacy of chemotherapy and radiation treatments.

The Phase 2/3 trials will be sponsored by Vtesse, a new biotech company that was formed specifically to evaluate the safety and efficacy of cyclodextrin for the treatment of NPC and ultimately obtain FDA labeling if the drug is effective.

This knowledge may be used to develop new ways for opening the blood - brain - barrier to increase the efficacy of the brain cancer drugs and for the design of treatment regimes that strengthens the integrity of the blood - brain barrier.»

After the success of a new drug treatment in adults with hepatitis C infection, a Saint Louis University pediatric researcher is testing the safety and efficacy of the medications in children.

Improved diagnostic tests are on the horizon, but we need huge efforts to increase their accuracy, use them for active case finding in the community, and eventually make them available in low income countries so as to inform treatment decisions and preserve the efficacy of any new antibiotic drugs for TB,» says lead author of the Commission Professor Keertan Dheda, University of Cape Town.

Groups have raised concerns about the evidence used to support the approval of some newer drugs, however, and the issue has been used to cast doubt on their efficacy and even to question treatment or deny reimbursement.

After participating in an 8 - week baseline period followed by 12 weeks of brivaracetam treatment, patients became eligible for long - term follow - up to monitor the drug's efficacy and safety.

However, the efficacy of this kind of cocktail treatment suffers when the drugs require access to different parts of the cell, a bit like fighting a battle by depositing all your archers on the same spot as your infantrymen.

Monies have gone to fund such projects as a postdoctoral fellow studying familial hypercholesterolemia, evaluating the efficacy and safety of a new drug for congenital hyperinsulinism, and identifying molecular targets for Pitt - Hopkins Syndrome treatments.

Finally, we know that treatment early in the disease course is associated with improved efficacy of drugs and better outcomes, such as reduced risk for surgery.

Exposure to atrazine while taking aromatase inhibitors for treatment of breast cancer could decrease the efficacy of the drug.

An accurate diagnosis is necessary for adequate patient treatment, a deeper understanding of the epidemiology of helminthiases, assessment of anthelmintic drug efficacy, and for monitoring the community - effectiveness of control programs [4], [5].

* The modified atkins diet which has been demonstrated to have similar efficacy to the classical ketogenic diet in the treatment of drug - resistant epilepsy and how it may be a slightly more practical option for achieving therapeutic nutritional ketosis.

However, drug safety and efficacy beyond 1 year of total treatment have not been established.

All emerging research points to one conclusion: turmeric meets or exceeds the efficacy of leading drugs in nearly every class of treatment, without side effects or other risks.

Such experimental designs are widely used to evaluate the efficacy of medical drugs prior to making such treatments available to the public.

Serum ALT and alkaline phosphatase are occasionally increased, but do not correlate well with abnormal liver function, efficacy of adulticide treatment, or risk of drug toxicity.

Currently Enrolling Cats: Efficacy of a New Drug for Treatment of Cats with Ronidazole - Resistant T. foetus infection

A lot of this is somewhat like what goes on in the medical business: Small, poorly controlled studies are used to proclaim the efficacy of some new drug or treatment.

For example, the Human Rights Tribunal of Ontario has dismissed claims of discrimination against the Ontario Drug Benefit Program on the basis that there was no Code - related reason for denying coverage, but rather a dispute over its efficacy and safety as a medical treatment (e.g. Kueber v. Ontario (Attorney General), 2014 HRTO 769).

The purpose of the trial is to evaluate the efficacy of using a family - based treatment program (Behaviour Exchange Systems Training; BEST Plus) versus a standard cognitive - behavioural individual treatment program for the youth, (Self Help for Alcohol / Other Drug problems and DEpression — Youth; SHADEY CBT), versus receiving both the family and the CBT intervention (COMBINED condition).

This study (NIDA #R01DA025616) is a randomized clinical trial (RCT) that will compare an experimental treatment (OutPatient Treatment for Adolescents) to an «active placebo» on key indices (drug use; mental health; behavioral, school, peer, and family functioning; and consumer satisfaction) from pre-treatment through 18 months in order to evaluate its efficacy for youth referred to outpatient treatment of co-occurring substance use and internalizing treatment (OutPatient Treatment for Adolescents) to an «active placebo» on key indices (drug use; mental health; behavioral, school, peer, and family functioning; and consumer satisfaction) from pre-treatment through 18 months in order to evaluate its efficacy for youth referred to outpatient treatment of co-occurring substance use and internalizing Treatment for Adolescents) to an «active placebo» on key indices (drug use; mental health; behavioral, school, peer, and family functioning; and consumer satisfaction) from pre-treatment through 18 months in order to evaluate its efficacy for youth referred to outpatient treatment of co-occurring substance use and internalizing treatment through 18 months in order to evaluate its efficacy for youth referred to outpatient treatment of co-occurring substance use and internalizing treatment of co-occurring substance use and internalizing problems.

Abstract: This study examined relationships among language use, mindfulness, and substance - use treatment outcomes in the context of an efficacy trial of mindfulness - based relapse prevention (MBRP) for adults with alcohol and other drug use (AOD) disorders.